Natriuretic peptides and the genomics of left-ventricular hypertrophy.

Heart Failure Clinics
Daniel L Dries

Abstract

Left-ventricular hypertrophy (LVH) is one of the strongest independent predictors of cardiovascular morbidity and mortality in the general population. Although hypertension and obesity are well-established, independent risk factors for the development of LVH, they explain less than 25% to 50% of the variance of left ventricular mass (LVM) in humans. A substantial body of evidence suggests that there is a genetic basis to the observed inter-individual variability in the susceptibility to the development of LVH. Given the continuous relationship between LVM and cardiovascular morbidity and mortality, elucidating the genetic determinants of inter-individual differences in the susceptibility to LVH is of considerable public health importance. It promises the opportunity to identify high-risk individuals for targeted intervention and may identify novel therapeutic targets for improved prevention and treatment strategies.

References

Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A KurtzC Bauer
Feb 1, 1995·Clinical and Experimental Pharmacology & Physiology·M L Zeidel
Oct 1, 1993·Journal of the American College of Cardiology·R R BrandtJ C Burnett
May 18, 1999·The Journal of Biological Chemistry·W YanQ Wu
Dec 14, 2002·Circulation Research·Toshihiro TsurudaJohn C Burnett
Jun 15, 2004·The American Journal of Cardiology·Ronald G VictorUNKNOWN Dallas Heart Study Investigators
Nov 18, 2004·JAMA : the Journal of the American Medical Association·Peter M OkinUNKNOWN LIFE Study Investigators
Jan 8, 2005·Proceedings of the National Academy of Sciences of the United States of America·Joyce C Y ChanQingyu Wu
Mar 22, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Jeetendra B PatelMargaret M Redfield
Nov 18, 2005·Cardiovascular Research·Toshio NishikimiHiroaki Matsuoka
Mar 2, 2006·Journal of Hypertension·Pankaj SharmaMorris J Brown
May 3, 2006·Circulation·Liliana R V CastroRodolphe Fischmeister
Mar 14, 2007·Journal of the American College of Cardiology·Faquan LiangAndrew A Protter
Nov 7, 2007·The Journal of Cell Biology·Igor I RybkinEric N Olson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.